

Deborah Schrag

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4471078/deborah-schrag-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120
papers

18,872
citations

63
h-index

131
g-index

131
ext. papers

22,092
ext. citations

9.2
avg, IF

6.63
L-index

#	Paper	IF	Citations
120	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 557-65	2.2	1084
119	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1803-10	2.2	943
118	Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. <i>Medical Care</i> , 2002 , 40, IV-3-18	3.1	919
117	Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1407-27	9.7	778
116	Primary care physicians who treat blacks and whites. <i>New England Journal of Medicine</i> , 2004 , 351, 575-84	59.2	724
115	Variations in morbidity after radical prostatectomy. <i>New England Journal of Medicine</i> , 2002 , 346, 1138-44	59.2	679
114	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
113	Overview of the SEER-Medicare Data. <i>Medical Care</i> , 2002 , 40, IV-3-IV-18	3.1	581
112	The influence of hospital volume on survival after resection for lung cancer. <i>New England Journal of Medicine</i> , 2001 , 345, 181-8	59.2	543
111	Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	454
110	Age and adjuvant chemotherapy use after surgery for stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 850-7	9.7	416
109	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. <i>Lancet Oncology</i> , 2006 , 7, 903-9	21.7	396
108	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
107	Care patterns in Medicare and their implications for pay for performance. <i>New England Journal of Medicine</i> , 2007 , 356, 1130-9	59.2	382
106	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015 , 1, 1051-9	13.4	377
105	Influence of hospital procedure volume on outcomes following surgery for colon cancer. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 284, 3028-35	27.4	375
104	Survival of blacks and whites after a cancer diagnosis. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 2106-13	27.4	371

103	Using navigators to improve care of underserved patients: current practices and approaches. <i>Cancer</i> , 2005 , 104, 848-55	6.4	346
102	The price tag on progress--chemotherapy for colorectal cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 317-9	59.2	345
101	A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. <i>Annals of Epidemiology</i> , 2007 , 17, 584-90	6.4	339
100	Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2380-5	2.2	327
99	Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 172-80	9.7	307
98	Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 513-8	2.2	303
97	Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. <i>Annals of Surgery</i> , 2002 , 236, 583-92	7.8	259
96	Desire for information and involvement in treatment decisions: elderly cancer patientsS preferences and their physiciansSperceptions. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5275-80	2.2	258
95	The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. <i>Annals of Internal Medicine</i> , 2003 , 139, 658-65	8	251
94	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1086-1095	2.2	235
93	Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. <i>Oncologist</i> , 2014 , 19, 637-8	5.7	220
92	The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2005 , 48, 1353-65	3.1	209
91	Individualized prediction of colon cancer recurrence using a nomogram. <i>Journal of Clinical Oncology</i> , 2008 , 26, 380-5	2.2	202
90	Cetuximab therapy and symptomatic hypomagnesemia. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1221-4	9.7	195
89	Delivery of preventive services to older adults by primary care physicians. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 473-81	27.4	195
88	Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3809-16	2.2	194
87	Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3999-4005	2.2	192
86	Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1732-40	2.2	188

85	Resurrecting treatment histories of dead patients: a study design that should be laid to rest. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2765-70	27.4	188
84	Use of surgery among elderly patients with stage IV colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3475-84	2.2	184
83	American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3631-7	2.2	179
82	Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. <i>Journal of Surgical Oncology</i> , 2003 , 83, 68-78; discussion 78-9	2.8	174
81	Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2757-64	2.2	172
80	Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2728-32	2.2	163
79	How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. <i>Cancer</i> , 2006 , 107, 1624-33 ⁴	6.4	158
78	Oncology Practice During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 2005-2006	27.4	144
77	Use of information resources by patients with cancer and their companions. <i>Cancer</i> , 2004 , 100, 2476-83	6.4	142
76	Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 669-685	27.4	139
75	Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 163-71	9.7	138
74	Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. <i>Journal of Clinical Oncology</i> , 2007 , 25, 233-7	2.2	138
73	Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5374-80	2.2	135
72	Physician visits prior to treatment for clinically localized prostate cancer. <i>Archives of Internal Medicine</i> , 2010 , 170, 440-50		117
71	Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 166-74	2.2	114
70	Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4796-802	2.2	107
69	Adherence to surveillance among patients with superficial bladder cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 588-97	9.7	103
68	The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. <i>Cancer</i> , 2005 , 104, 1149-57	6.4	97

67	Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. <i>Blood</i> , 2001 , 98, 3234-40	2.2	90
66	Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2007 , 14, 264-8	8.6	87
65	Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. <i>Annals of Internal Medicine</i> , 2003 , 139, 649-57	8	85
64	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 757-770	19.4	82
63	Development and Validation of the PREMM Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2165-2172	2.2	82
62	Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. <i>Urology</i> , 2005 , 65, 1118-25	1.6	78
61	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. <i>Cancer Medicine</i> , 2018 , 7, 525-535	4.8	71
60	Attribution of deaths following cancer treatment. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1044-5	4.5	70
59	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. <i>International Journal of Radiation Oncology Biological Physics</i> , 2017 , 135, 406-410	4	66
58	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Health and Quality of Life Outcomes</i> , 2016 , 14, 24	3	63
57	Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. <i>Gut</i> , 2016 , 65, 563-74	19.2	62
56	Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. <i>Journal of Oncology Practice</i> , 2013 , 9, 60s-63s	3.1	58
55	Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. <i>Annals of Epidemiology</i> , 2014 , 24, 666-72, 672.e1-2	6.4	54
54	Fragmentation of care for frequently hospitalized urban residents. <i>Medical Care</i> , 2006 , 44, 560-7	3.1	47
53	Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. <i>Medical Care</i> , 2002 , 40, IV-96-103	3.1	42
52	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. <i>Medical Care</i> , 2016 , 54, e47-54	3.1	42
51	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. <i>Clinical Trials</i> , 2017 , 14, 255-263	2.2	37
50	Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 362	9.7	37

49	Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. <i>Statistics in Medicine</i> , 2007 , 26, 2017-35	2.3	37
48	Using propensity scores to estimate the cost-effectiveness of medical therapies. <i>Statistics in Medicine</i> , 2006 , 25, 1561-76	2.3	35
47	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018788620	2.3	32
46	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. <i>Cancer</i> , 2005 , 104, 1871-84	6.4	32
45	Accelerating anticancer drug development - opportunities and trade-offs. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 777-786	19.4	32
44	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 947-957	5.2	28
43	Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 276-285	8.6	27
42	Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	26
41	Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1123-30	7.3	25
40	Hospitalization burden and survival among older glioblastoma patients. <i>Neuro-Oncology</i> , 2014 , 16, 1530-40	4	25
39	Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer. <i>Journal of the American Statistical Association</i> , 2016 , 111, 1075-1095	2.8	21
38	Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1456-66	4	16
37	Acute kidney injury in patients treated with immune checkpoint inhibitors 2021 , 9,		15
36	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2880-2888	4	12
35	Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 301-311	4.8	12
34	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018 , 5, e10070	2.5	12
33	A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. <i>Patient Education and Counseling</i> , 2017 , 100, 1527-1536	3.1	11
32	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021 , 13,	6.6	11

31	Defining optimal treatment for stage II colon cancer: does decision analysis help?. <i>Gastroenterology</i> , 1999 , 117, 1005-8	13.3	10
30	Hospital variation in sphincter preservation for elderly rectal cancer patients. <i>Journal of Surgical Research</i> , 2014 , 191, 161-8	2.5	9
29	An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1799-802	2.2	9
28	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019 , 24, 945-954	5.7	9
27	Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. <i>Journal of Oncology Practice</i> , 2014 , 10, e360-7	3.1	8
26	Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1013-21	9.7	8
25	Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). <i>Leukemia Research</i> , 2014 , 38, 1420-4	2.7	7
24	Dartmouth Atlas Area-Level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients?. <i>Health Services Research</i> , 2016 , 51, 1584-94	3.4	7
23	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019 , 124, 40-46	5.6	7
22	Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. <i>Gastric Cancer</i> , 2017 , 20, 811-824	7.6	6
21	Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. <i>Cancer Medicine</i> , 2020 , 9, 2019-2029	4.8	6
20	Diffusion of Bevacizumab Across Oncology Practices: An Observational Study. <i>Medical Care</i> , 2018 , 56, 69-77	3.1	6
19	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 92-102	7.1	6
18	Deep Natural Language Processing to Identify Symptom Documentation in Clinical Notes for Patients With Heart Failure Undergoing Cardiac Resynchronization Therapy. <i>Journal of Pain and Symptom Management</i> , 2020 , 60, 948-958.e3	4.8	5
17	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021 , 4, e21111113	10.4	5
16	A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 2405	27.4	5
15	Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz058	4.6	4
14	Risk charts: putting cancer in context. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1584-5; author reply 1585-6	9.7	3

13	Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2018 , 3, 382-390	3.3	2
12	Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. <i>JAMA Oncology</i> , 2017 , 3, 101-104	13.4	2
11	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2117547	10.4	2
10	Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 102-102	2.2	1
9	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021 , 127, 1387-1394	6.4	1
8	Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review. <i>Cancer Medicine</i> , 2021 , 10, 7277-7288	4.8	1
7	Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39). <i>Lung Cancer</i> , 2021 , 162, 1-8	5.9	1
6	Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data. <i>JAMA Internal Medicine</i> , 2014 , 174, 1468-9	11.5	0
5	Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab045	4.6	0
4	Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 622-630	5.2	0
3	Racial Disparities in Colorectal Cancer Recurrence and Mortality: Equitable Care, Inequitable Outcomes?. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 656-657	9.7	0
2	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.. <i>Oncologist</i> , 2022 , 27, 292-298	5.7	
1	Integration of patient-reported adverse events into a phase II chemotherapy treatment trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6583-6583	2.2	